Research overview: remdesivir for feline infectious peritonitis

Remdesivir, a prodrug that is metabolized to the active nucleoside analog GS-441524, became a legally available, regulated treatment option for FIP in some countries, offering an injectable alternative to unregulated GS-441524 sources. Reported case series and clinical experience describe high remission rates similar to those seen with the parent compound, often transitioning cats from injectable remdesivir to oral therapy over a multi-week course. This overview synthesizes the treatment literature and clinical reports rather than one citation, describing the pharmacologic relationship between remdesivir and GS-441524, why regulatory availability mattered for owners and veterinarians, and how the emergence of legitimate supply channels improved access to curative antiviral therapy for a disease once considered hopeless.